Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?

While LeMaitre Vascular, Inc. (NASDAQ:LMAT) might not have the largest market cap around , it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGM. The company is now trading at yearly-high levels following the recent surge in its share price. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. But what if there is still an opportunity to buy? Let’s examine LeMaitre Vascular’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

See our latest analysis for LeMaitre Vascular

Is LeMaitre Vascular Still Cheap?

According to our valuation model, LeMaitre Vascular seems to be fairly priced at around 1.6% below our intrinsic value, which means if you buy LeMaitre Vascular today, you’d be paying a reasonable price for it. And if you believe the company’s true value is $90.95, then there isn’t much room for the share price grow beyond what it’s currently trading. In addition to this, LeMaitre Vascular has a low beta, which suggests its share price is less volatile than the wider market.

What does the future of LeMaitre Vascular look like?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by 49% over the next couple of years, the future seems bright for LeMaitre Vascular. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? LMAT’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping tabs on LMAT, now may not be the most optimal time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

It can be quite valuable to consider what analysts expect for LeMaitre Vascular from their most recent forecasts. So feel free to check out our free graph representing analyst forecasts.

If you are no longer interested in LeMaitre Vascular, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.